Current treatment of Parkinson's disease;Therapie des idiopathischen Parkinson-syndroms

Deutsches Arzteblatt

Volumn 104, Issue 37, 2007, Pages

  Wojtecki, Lars ^a   Südmeyer, Martin ^a   Schnitzler, Alfons ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Deep brain stimulation; Dopamine agonists; Levodopa; Motor fluctuations; Parkinsons's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; DOPAMINERGIC SYSTEM; DYSKINESIA; GERMANY; GROUPS BY AGE; HUMAN; MEDICAL SOCIETY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLOGY; PARKINSON DISEASE; PRACTICE GUIDELINE; RECEPTOR UPREGULATION; TREATMENT RESPONSE; TREMOR;

EID: 34948877499     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. de Rijk MC, Launer LJ, Berger K et al.: Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: 21-3.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
3. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9.
4. Oertel WH et al.: Parkinson-Syndrome. In: Diener HC, ed.: Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag, 2005; 48-72.
5. Hoehn MM: The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10: 331-9.
6. Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-305.
7. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama 2000; 284: 1931-8.
8. Rinne UK, Bracco F, Chouza C et al.: Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48: 363-8.
9. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-91.
10. The Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-8.
11. Goetz CG, Leurgans S, Pappert EJ, Raman R, Sterner AB: Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078-82.
12. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
13. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.
14. Kurth MC, Adler CH, Hilaire MS et al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81-7.
15. Rinne UK, Larsen JP, Siden A, Worm-Petersen J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51: 1309-14.
16. Henchcliffe C, Schumacher HC, Burgut FT: Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 2005; 5: 811-21.
17. Rascol O, Brooks DJ, Melamed E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-54.
18. Crosby NJ, Deane KH, Clarke CE: Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003(2): CD003467.
19. Crosby N, Deane KH, Clarke CE: Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003(1): CD003468.
20. Schwab RS, Amador LV, Lettvin JY: Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951; 56: 251-3.
21. Poewe W, Wenning GK: Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000; 15: 789-94.
22. Deep-Brain Stimulation for Parkinson's Disease Study Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345: 956-63.
23. Deuschl G, Schade-Brittinger C, Krack P et al.: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
24. Emre M, Aarsland D, Albanese A et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
25. The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-63.